Pathological diaphragmatic invasion by colorectal liver metastases is associated with RAS mutation, peritoneal recurrence and worse survival

Okuno, Masayuki; Gourmard, Claire; Mizuno, Takashi; Omichi, Kiyohiko; Tzeng, Ching Wei D.; Chun, Yun Shin; Lee, Jeffrey E.; Vauthey, Jean Nicolas; Conrad, Claudius

doi:10.1016/j.hpb.2017.08.020

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A positive margin (HR 3.36) and RAS mutation (HR 1.629) were independently associated with worse OS (40). Similarly, presence of RAS mutation is associated for more diaphragmatic invasion by liver metastasis requiring major hepatic resection and diaphragmatic resection (41). Margonis et al suggested that anatomical resections with more extensive surgical margins could counterbalance this adverse and more invasive genetic profile associated to RAS mutation (42).…”

Section: Impact Of Ras Mutation In Liver Metastases (Lim)mentioning

confidence: 99%

“…However, the role of tumor biology and RAS mutations in the context of PM remained unclear until recent studies (53)(54)(55)(56)(57). RAS mutation is associated with peritoneal recurrence after resection of LiM (41) and prevalence of RAS mutations appears higher in PM than in LiM, up to 58% (55). In 524 patients who underwent CRS and HIPEC for CRC PM, 378 had known RAS/ RAF status.…”

Section: Impact Of Ras Mutation In Peritoneal Metastases (Pm)mentioning

confidence: 99%

See 1 more Smart Citation

RAS mutation: site of disease and recurrence pattern in colorectal cancer

Bonnot¹,

Passot

2019

Chin. Clin. Oncol.

View full text Add to dashboard Cite

Somatic mutation status in metastatic colorectal cancer (CRC), and namely mutational activation of the Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogene, is becoming more and more relevant in clinical practice. In this review, we describe the current data about the importance of associations between the mutational activation status of the KRAS oncogene and clinical outcomes, prognosis and metastatic patterns of CRC. The presence of a KRAS mutation is detected in approximately 30-50% of CRC and represents a powerful predictor of oncologic outcomes. It is associated with low response to systemic chemotherapy and for insensitivity to the anti-EGFR antibodies in the preoperative setting. It is more frequently associated with right colon cancer. In non-metastatic patients, KRAS mutation leads to more aggressive disease with shorter recurrence free survival (RFS) and more lung recurrences. After resection of CRC liver metastases (LiM), KRAS mutation is directly associated with increased risk of recurrence, worse overall survival (OS), and a distinct metastatic pattern with more invasive intrahepatic recurrence and increased recurrence outside of the liver, particularly in the lung, the peritoneum, and even in uncommon metastatic sites such as the brain and bones. As metastasectomy with curative intent is increasingly considered, a comprehensive approach of tumor biology is required to face the specific challenge of patients with metastatic CRCs. Thus, as it represents one of the strongest predictors of oncologic outcomes, integrating the KRAS mutational status at all the different stages of patient care appears crucial in order to adapt both medical and surgical strategies.

show abstract

Section: Impact Of Ras Mutation In Liver Metastases (Lim)mentioning

confidence: 99%